Get the Stockscreener App
29.12
2.05%
-0.61
Pre-market:
29.07
-0.05
-0.17%
Tg Therapeutics Inc stock is traded at $29.12, with a volume of 1.46M.
It is down -2.05% in the last 24 hours and down -0.55% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$29.73
Open:
$29.98
24h Volume:
1.46M
Relative Volume:
0.74
Market Cap:
$4.62B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-264.73
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-3.93%
1M Performance:
-0.55%
6M Performance:
+1.39%
1Y Performance:
-11.52%
1-Day Range:
$28.70
$29.98
1-Week Range:
$28.60
$30.73
52-Week Range:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
29.12 | 4.72B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.52 | 118.13B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
775.06 | 79.79B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
850.87 | 52.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.96 | 46.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
352.00 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
RSI Check: Should you avoid TG Therapeutics Inc stock right nowQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt - 富途牛牛
TG Therapeutics stock maintains Buy rating at B.Riley on strong Briumvi growth - Investing.com India
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - AOL.com
JP Morgan Adjusts Price Target for TGTX, Maintains Overweight Ra - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price - MarketBeat
TG Therapeutics, Inc. (TGTX) Investor Outlook: Exploring the 52.42% Potential Upside and Strategic Positioning in Biotechnology - DirectorsTalk Interviews
Quarterly Trades: Will TG Therapeutics Inc benefit from AI trendsWeekly Gains Report & Fast Momentum Entry Tips - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation - Sahm
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Weakness And BRIUMVI Growth Assumptions - Yahoo Finance
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Canada
TG Therapeutics to present BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
BRIUMVI multiple sclerosis data to headline San Diego ACTRIMS forum - Stock Titan
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with 43.77% Potential Upside - DirectorsTalk Interviews
Understanding Momentum Shifts in (TGTX) - Stock Traders Daily
TG Therapeutics Achieves 8.54% Return; Birkenstock Reports -31.21% Loss - Markets Mojo
Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX) - The Globe and Mail
Is TG Therapeutics (TGTX) Pricing Reflecting Its Strong DCF And P/E Valuation Signals? - Sahm
Why TG Therapeutics (TGTX) Is Up 6.9% After Issuing 2026 BRIUMVI-Centric Revenue Guidance And What's Next - Sahm
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Moving Averages: Should you avoid TG Therapeutics Inc stock right nowJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Goldman Sachs Raises Price Target for TG Therapeutics (TGTX) to $39 | TGTX Stock News - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Trading 7.5% HigherHere's Why - MarketBeat
TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) - Seeking Alpha
HC Wainwright Forecasts TG Therapeutics FY2025 Earnings - MarketBeat
TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook - The Globe and Mail
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries - Intellectia AI
TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities - The Globe and Mail
TG Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - MarketBeat
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Mom - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpTime to Buy? - MarketBeat
TGTX Stock Surges Over 12% Amid Positive Market Movement - GuruFocus
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics shares hit highest since November, last up 12.9% after prelim 2025 sales top estimate - marketscreener.com
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? - Asianet Newsable
Why TG Therapeutics Stock Is Moving Today - Benzinga
TG Therapeutics steigert Umsatzprognose für 2026 und übertrifft Umsatzprognose für 2025 - TradingView — Track All Markets
TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat - TradingView — Track All Markets
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED) - Benzinga
Retail traders are piling into TG Therapeutics – what’s driving the chatter? - MSN
In the Wake of TG Therapeutics, Inc.'s (NASDAQ:TGTX) Latest US$225m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - Futubull
Avoiding Lag: Real-Time Signals in (TGTX) Movement - Stock Traders Daily
SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Menafn
Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.65%
3.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):